Novel Approaches to Target MECOM/EVI1 in AML

Last updated: December 22, 2023
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

Biological characterization of AML with MECOM or atypical 3q26 rearrangements

Clinical Study ID

NCT05839392
AML2623
  • Ages > 18
  • All Genders

Study Summary

This is an academic, no-profit, multicenter, biological, non-pharmacologic study aimed at characterizing genome, transcriptome and proteome of patients affected by AML with MECOM or atypical 3q26 rearrangements.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • AML with MECOM or atypical 3q26 rearrangements.
  • Age ≥18.
  • Signed written informed consent according to ICH/EU/GCP and national local laws.

Exclusion

Exclusion Criteria:

  • None

Study Design

Total Participants: 24
Treatment Group(s): 1
Primary Treatment: Biological characterization of AML with MECOM or atypical 3q26 rearrangements
Phase:
Study Start date:
December 13, 2023
Estimated Completion Date:
December 31, 2026

Study Description

This is an academic, no-profit, multicenter, biological, non-pharmacologic study aimed at characterizing genome, transcriptome and proteome of patients affected by AML with MECOM or atypical 3q26 rearrangements. To this end, BM samples and formalin fixed/paraffin-embedded BM biopsies will be collected at enrolment, before and after treatment, at relapse.

Connect with a study center

  • Ematologia

    Piacenza,
    Italy

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.